01 March 2024
01 March 2024
The vaccine showed a 77.8% efficacy against RSV-associated LRTD after the second season.
According to the findings, Zeposia treatment resulted in a notably low annualised relapse rate of 0.098.
Artiva has also investigated AlloNK in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
The trial is designed to assess the tolerability, safety, pharmacokinetics and pharmacodynamics of IBI3002.
To manoeuvre past the clinical deficiencies stated in the recent CRL, Minerva must provide additional safety and efficacy data for roluperidone, including data to support concomitant antipsychotic usage.
TrialPioneer is tailored to enhance the workflow of medical directors, clinicians, and statisticians.
After a challenging few years post-pandemic, industry professionals believe diagnostic testing is back on track and ready to be implemented widely in modern healthcare.
On Rare Disease Day 2024, Clinical Trials Arena investigates if and how rare disease trials can tackle environmental sustainability.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
